Myriad Plans to Sell Harder During Weak Economy; Reports Slowdown in Revenue Growth
August 26, 2009
Myriad Plans to Sell Harder During Weak Economy; Reports Slowdown in Revenue Growth
More OB/GYN sales reps, expanded direct-to-consumer marketing campaigns, and more company-hired physicians reaching out to other doctors are a few “initiatives [that] will be beneficial to the company in combating this weak economy,” Myriad CEO Peter Meldrum said during an earnings call this week.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 2, 2012 / Pharmacogenomics Reporter - Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010 / Pharmacogenomics Reporter - Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 6, 2013 / Pharmacogenomics Reporter